Skip to main content
SpringerLink
Log in

Body Mass Index and the Efficacy of Acid-Mediating Agents for GERD

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

In studies of the association between obesity and gastroesophageal reflux, one subject that has received very little attention is the effect excess body mass may have on the effectiveness of acid-mediating agents. The lack of systematic research may reflect the perceived high clinical efficacy of drugs like proton pump inhibitors. Both proton pump inhibitors and histamine type 2 receptor antagonists have low rates of significant adverse events; if there are differences in the side effect profiles based on BMI, it is unlikely such associations would be detected. Also, while the metabolism of many drugs can be affected by body mass, it is not clear that such a relationship exists with acid-mediating agents. Nevertheless, there is evidence that body mass index may indeed be associated with the efficacy of proton pump inhibitors and histamine type 2 receptor antagonists. This review will examine that evidence and consider some of the possible pharmacokinetic effects that might relate to body mass index.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Blouin RA, Warren GW (1999) Pharmacokinetic considerations in obesity. J Pharm Sci 88:1–7. doi:10.1021/js980173a

    Article  PubMed  CAS  Google Scholar 

  2. Cheymol G (2000) Effects of obesity on pharmacokinetics: implications for drug therapy. Clin Pharmacokinet 39:215–231. doi:10.2165/00003088-200039030-00004

    Article  PubMed  CAS  Google Scholar 

  3. Lesser G, Deutsch S (1967) Measurement of adipose tissue blood flow and perfusion in man by uptake of 85Kr. J Appl Physiol 23:621–632

    PubMed  CAS  Google Scholar 

  4. Barak N, Ehrenpreis ED, Harrison JR, Sitrin MD (2002) Gastro-oesophageal reflux disease in obesity: pathophysiological and therapeutic considerations. Obes Rev. 3:9–15. doi:10.1046/j.1467-789X.2002.00049.x

    Article  PubMed  CAS  Google Scholar 

  5. Benedeck IH, Blouin A, McNamara PJ (1984) Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol 18:941–946

    Google Scholar 

  6. Andersson T (1996) Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole, and pantoprazole. Clin Pharmacokinet 31:9–28

    PubMed  CAS  Google Scholar 

  7. Feldman M, Burton ME (1990) Histamine2-receptor antagonists. N Engl J Med 323:1672–1680

    Google Scholar 

  8. Somogyi A, Gugler R (1983) Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet 8:463–495

    Article  PubMed  CAS  Google Scholar 

  9. McColl KEL, Kennerley P (2002) Proton pump inhibitors–differences emerge in hepatic metabolism. Dig Liver Dis. 34:461–467. doi:10.1016/S1590-8658(02)80102-5

    Article  PubMed  CAS  Google Scholar 

  10. Horn J (2006) Review article: understanding the pharmacodynamic and pharmacokinetic differences between proton-pump inhibitors- focus on pKa and metabolism. Aliment Pharmacol Ther Symp Ser 2:340–350. doi:10.1111/j.1746-6342.2006.00065.x

    Article  CAS  Google Scholar 

  11. Hoogerwerf WA, Pasricha PJ (2006) Pharmacotherapy of gastric acidity, peptic ulcers and gastroesophageal reflux disease. In: Goodman and Gillman’s pharmacology, 11th edn. McGraw-Hill, New York

  12. Sanyal AJ (2002) AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123:1705–1725. doi:10.1053/gast.2002.36572

    Article  PubMed  Google Scholar 

  13. Kolwankar D, Vuppalanchi R, Ethell B, Jones DR, Wrighton SA, Hall SD et al (2007) Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol. 5:388–393. doi:10.1016/j.cgh.2006.12.021

    Article  PubMed  CAS  Google Scholar 

  14. Davis RL, Quenzer RW, Bozigian HP, Warner CW (1990) Pharmacokinetics of ranitidine in morbidly obese women. Drug Intell Clin Pharm 24:1040–1043

    CAS  Google Scholar 

  15. Abernethy DR, Greenblatt DJ, Matlis R, Gugler R (1984) Cimetidine disposition in obesity. Am J Gastroenterol 79:91–94

    PubMed  CAS  Google Scholar 

  16. McDougall NI, Johnston BT, Collins JS, McFarland RJ, Love AH (1998) Three- to 4.5-year prospective study of prognostic indicators in gastroesophageal reflux disease. Scand J Gastroenterol 33:1016–1022. doi:10.1080/003655298750026688

    Article  PubMed  CAS  Google Scholar 

  17. Talley NJ, Armstrong D, Junghard O, Wiklund I (2006) Predictors of treatment response in patients with non-erosive reflux disease. Aliment Pharmacol Ther 24:371–376. doi:10.1111/j.1365-2036.2006.02983.x

    Article  PubMed  CAS  Google Scholar 

  18. Jacobson BC, Somers SC, Fuchs CF, Kelly CP, Camargo CA Jr (2006) Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 354:2340–2348. doi:10.1056/NEJMoa054391

    Article  PubMed  CAS  Google Scholar 

  19. Hampel H, Abraham N, El-Serag H (2005) Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 143:199–211

    PubMed  Google Scholar 

  20. Jacobson BC, Delemos B, Sun Y et al (2007) Treatment outcomes with rabeprazole (RAB) 20 mg vs. placebo (PBO) in overweight/obese patients with nonerosive reflux disease (NERD): analysis of 2 US multicenter trials. Gastroenterology 132(suppl 2):A-493 (Abstract)

    Google Scholar 

  21. Kahrilas PJ, Miner P, Johanson J, Mao L, Jokubaitis L, Sloan S (2005) Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci 50:2009–2018. doi:10.1007/s10620-005-3000-3

    Article  PubMed  CAS  Google Scholar 

  22. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, Mc Carthy JH et al (1988) Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95:903–912

    PubMed  CAS  Google Scholar 

  23. Jacobson BC, DeLemos B, Sun Y et al (2007) PPI Efficacy in overweight/obese patients with erosive GERD: rabeprazole (RAB) 20 mg vs. omeprazole (OME) 20 mg. Am J Gastroenterol 102:S150 (Abstract 89)

    Google Scholar 

  24. Pace F, Annese V, Prada A, Zambelli A, Casalini S, Nardini P et al (2005) Italian Rabeprazole Study Group: rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. a randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole. Dig Liver Dis 37:741–750. doi:10.1016/j.dld.2005.04.026

    Article  PubMed  CAS  Google Scholar 

  25. Sharma P, Vakil N, Monyak JT et al (2007) Effect of obesity on symptom resolution in patients with gastroesophageal reflux disease (GERD). Am J Gastroenterol 102:S139–S140 (Abstract 61)

    Google Scholar 

  26. Vakil N, Sharma P, Monyak JT et al (2007) Is obesity the cause of reduced healing rates in advanced grades of erosive esophagitis (EE)? Am J Gastroenterol 102:S445 (Abstract 889)

    Google Scholar 

  27. Wang WH, Huang JQ, Zheng GF, Wong WM, Lam SK, Karlberg J et al (2005) Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain? a meta-analysis. Arch Intern Med 165:1222–1228. doi:10.1001/archinte.165.11.1222

    Article  PubMed  CAS  Google Scholar 

  28. Numans ME, Lau J, de Wit NJ, Boris PA (2004) Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 140:518–527

    PubMed  CAS  Google Scholar 

  29. Wilson LJ, Ma W, Hirschowitz BI (1999) Association of obesity with hiatal hernia and esophagitis. Am J Gastroenterol 94:2840–2844. doi:10.1111/j.1572-0241.1999.01426.x

    Article  PubMed  CAS  Google Scholar 

  30. Pandolfino JE, El-Serag HB, Zhang Q, Shah N, Ghosh SK, Kahrilas PJ (2006) Obesity: a challenge to esophagogastric junction integrity. Gastroenterology 130:639–649. doi:10.1053/j.gastro.2005.12.016

    Article  PubMed  Google Scholar 

  31. Wu JC, Mui LM, Cheung CM, Chan Y, Sung JJ (2007) Obesity is associated with transient lower esophageal sphincter relaxation. Gastroenterology 132:883–889. doi:10.1053/j.gastro.2006.12.032

    Article  PubMed  Google Scholar 

  32. Pirttiaho HI, Salmela PI, Sotaniemi EA, Pelkonen RO, Pitkänen U, Luoma PV (1984) Drug metabolism in diabetic subjects with fatty livers. Br J Clin Pharmacol 18:895–899

    PubMed  CAS  Google Scholar 

  33. Leclercq I, Horsmans Y, Desager JP, Delzenne N, Geubel AP (1998) Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. J Hepatol 28:410–416. doi:10.1016/S0168-8278(98)80314-0

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Brian C. Jacobson is supported by a grant from the National Institutes of Health (DK K08-070706). Dr. Jacobson also serves as a consultant for Ortho-McNeill, LLC, and Eisai, Inc. The scientific roundtable was funded by Eisai, Inc. and PriCara, a Unit of Ortho-McNeil, Inc. International Meetings and Science, Inc. organized the roundtable and provided editorial support.

Author information

Authors and Affiliations

  1. Section of Gastroenterology, Department of Medicine, Boston University Medical Center, 85 East Concord Street, Room 7721, Boston, MA, 02118, USA

    Brian C. Jacobson

Authors
  1. Brian C. Jacobson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brian C. Jacobson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jacobson, B.C. Body Mass Index and the Efficacy of Acid-Mediating Agents for GERD. Dig Dis Sci 53, 2313–2317 (2008). https://doi.org/10.1007/s10620-008-0414-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-008-0414-8

Keywords

Search

Navigation